KalVista Pharmaceuticals, Inc. - stock earnings
KALV Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q3 | -25.3 million USD | ? USD |
| 2023Q1 | -21.3 million USD | ? USD |
| 2022Q4 | -22.3 million USD | ? USD |
| 2022Q3 | -23.0 million USD | ? USD |
| 2022Q2 | -24.1 million USD | ? USD |
| 2022Q1 | -22.5 million USD | ? USD |
| 2021Q4 | -19.7 million USD | ? USD |
| 2021Q3 | -16.1 million USD | ? USD |
| 2021Q2 | -15.0 million USD | ? USD |
| 2021Q1 | -10.0 million USD | ? USD |
| 2020Q4 | -10.4 million USD | ? USD |
KALV Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -74.9 million USD | ? USD |
| 2022 | -68.5 million USD | ? USD |
| 2021 | -44.5 million USD | 12.7 million USD |
| 2020 | -29.1 million USD | 12.7 million USD |
| 2019 | -20.8 million USD | 16.1 million USD |
| 2018 | -15.8 million USD | 8.4 million USD |
| 2017 | -18.6 million USD | 1.5 million USD |
| 2016 | -6.6 million USD | 7000 USD |
| 2015 | -7.2 million USD | 1.8 million USD |
| 2014 | -5.7 million USD | 415000 USD |
| 2013 | -2.1 million USD | 1.5 million USD |
KALV
Price: $10.78
52 week price:
Earnings Per Share: -3.12 USD
P/E Ratio: -5.02
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 731100
Ebitda: -22.6 millionMarket Capitalization: 498.2 million